Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) Other Non Operating Income: 2012-2025

Historic Other Non Operating Income for Aytu Biopharma (AYTU) over the last 12 years, with Sep 2025 value amounting to $3.8 million.

  • Aytu Biopharma's Other Non Operating Income rose 31.39% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$799,000, marking a year-over-year decrease of 116.70%. This contributed to the annual value of -$1.7 million for FY2025, which is 57.47% up from last year.
  • Per Aytu Biopharma's latest filing, its Other Non Operating Income stood at $3.8 million for Q3 2025, which was up 138.38% from -$9.9 million recorded in Q2 2025.
  • In the past 5 years, Aytu Biopharma's Other Non Operating Income ranged from a high of $3.8 million in Q3 2025 and a low of -$9.9 million during Q2 2025.
  • Over the past 3 years, Aytu Biopharma's median Other Non Operating Income value was $1.5 million (recorded in 2024), while the average stood at -$65,818.
  • Per our database at Business Quant, Aytu Biopharma's Other Non Operating Income soared by 5,577.50% in 2022 and then crashed by 773.96% in 2025.
  • Aytu Biopharma's Other Non Operating Income (Quarterly) stood at -$257,000 in 2021, then surged by 645.91% to $1.4 million in 2022, then plummeted by 141.13% to -$577,000 in 2023, then surged by 622.70% to $3.0 million in 2024, then soared by 31.39% to $3.8 million in 2025.
  • Its Other Non Operating Income stands at $3.8 million for Q3 2025, versus -$9.9 million for Q2 2025 and $2.3 million for Q1 2025.